GeoVax Labs, Inc.

Good morning and welcome everyone to the GeoVax fourth quarter year-end 2020 corporate update call. I am Jason with CourseCall and will facilitate today's call. With me are David Dodd, Chairman and CEO, Mark Reynolds, Chief Financial Officer, and Mark Newman, Ph.D., Chief Scientific Officer. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. to ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I'd now like to turn the conference over to Scott Gordon of Core IR who will provide a forward-looking statement regarding this call and information herein.

Thank you, Jason. Please note the following. Certain statements in this presentation may constitute forward-looking statements. within the meaning of the private securities litigation reform act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use G of X's vaccine will effectively prevent targeted infections in humans. G of X's vaccines will receive regulatory approvals necessary to be licensed and marketed. G of X raises required capital to complete vaccine development. There is development of competitive products that may be more effective or easier to use than G of X's products. G of X will be able to enter into favorable manufacturing and distribution agreements and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission, including those set forth at risk factors in GeoVax's 410 . It is now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd. David, please go ahead.

Good morning. and thank you for participating in the 2020 fourth quarter year-end GeoVax quarterly update call. At the cusp of third to fourth quarter 2020, GeoVax capitalized the company and achieved the NASDAQ listing, securing significant resources and support of accelerating our development programs towards clinical development. We are focused on delivering meaningful results and value milestones over the next 12 to 15 months. Our focus is on advancing our priority programs related to COVID-19 and immuno-oncology, developing increased value for shareholders, stakeholders, and public health worldwide. In October, we announced a license agreement with NIH providing GeoVax full access to and use of critical NIH patents and materials in support of COVID-19 vaccine product development, clinical development, and continued progress through FDA registration, manufacturing and commercialization. Executing that license, pardon me, underscores our commitment to and confidence in our unique vaccine development approach relative to COVID-19. In November, we announced another license with NIH providing GeoVax full access to and use of the NIH patents and materials in support of vaccine product development against numerous pathogens, including within cancer immunotherapy. This additional broad-based product target license underscores our focus and commitment to advancing a high-value, meaningful product pipeline through registration and commercialization. Once we decide to advance a specific product into clinical development, we anticipate executing a license with NIH similar to our COVID-19 agreement. In January, we announced receipt of NIH funding in support of our COVID-19 vaccine development program. There is increasing evidence that the COVID-19 virus will continue to evolve, requiring expanded virus variant coverage, otherwise requiring annual reconfigured vaccines similar to what is necessary relative to influenza vaccination.